Vincare Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 05-07-2024
- Paid Up Capital ₹ 0.10 M
as on 05-07-2024
- Company Age 15 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Revenue -32.50%
(FY 2017)
- Profit -10456.12%
(FY 2017)
- Ebitda -72.09%
(FY 2017)
- Net Worth -258.43%
(FY 2017)
- Total Assets -2.71%
(FY 2017)
About Vincare Pharma
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Lakshmanan Pichandy and Venu Sarma serve as directors at the Company.
- CIN/LLPIN
U74900MH2009PTC195300
- Company No.
195300
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Aug 2009
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Vincare Pharma Private Limited offer?
Vincare Pharma Private Limited offers a wide range of products and services, including Vitamin & Multivitamin Injections, Methylcobalamin Injection, Pharmaceutical Syrup, Multivitamin Syrup & Drops, Mineral Supplement, Iron Syrup.
Who are the key members and board of directors at Vincare Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lakshmanan Pichandy  | Managing Director | 28-Aug-2009 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venu Sarma | Director | 28-Aug-2009 | Current |
Financial Performance of Vincare Pharma.
Vincare Pharma Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 32.5% decrease. The company also saw a substantial fall in profitability, with a 10456.12% decrease in profit. The company's net worth observed a substantial decline by a decrease of 258.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vincare Pharma?
In 2017, Vincare Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vincare Pharma?
Unlock and access historical data on people associated with Vincare Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vincare Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vincare Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
